Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Providence County
    4. ›
  4. Lincoln
    5. ›
  5. Calista Therapeutics, Inc.

Calista Therapeutics, Inc.

Company claim

Is this your business?

Get access!

Company Details

Name: Calista Therapeutics, Inc.
Jurisdiction: Rhode Island
Entity type: Foreign Corporation
Status: Revocation
Date of Organization in Rhode Island: 02 May 2014 (11 years ago)
Date of Dissolution: 18 Jun 2025 (2 months ago)
Date of Status Change: 18 Jun 2025 (2 months ago)
Identification Number: 000929141
ZIP code: 02865
City: Lincoln
County: Providence County
Place of Formation: DELAWARE
Purpose: BIOTECHNOLOGY
Principal Address: Google Maps Logo 32 RIVERSIDE DRIVE, LINCOLN, RI, 02865, USA

Industry & Business Activity

NAICS

541714 Research and Development in Biotechnology (except Nanobiotechnology)

This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries. Learn more at the U.S. Census Bureau

Companies doing Research and development in biotechnology (except nanobiotechnology)

Agent

Name Role Address
ANDREW PETER MALLON Agent 32 RIVERSIDE DRIVE, LINCOLN, RI, 02865, USA

PRESIDENT

Name Role Address
ANDREW P. MALLON PRESIDENT 32 RIVERSIDE DRIVE LINCOLN, RI 02865 USA

Commercial and government entity program

CAGE number:
5NML3
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-06-08
CAGE Expiration:
2028-06-22
SAM Expiration:
2024-06-08

Contact Information

POC:
ANDREW P . MALLON

Filings

Number Name File Date
202448744430 Annual Report 2024-03-17
202327119010 Annual Report 2023-02-01
202220877620 Annual Report 2022-07-08
202220153670 Revocation Notice For Failure to File An Annual Report 2022-06-27
202187601870 Annual Report 2021-01-22

USAspending Awards / Contracts

Procurement Instrument Identifier:
INL12PX01434
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PO
Action Obligation:
$19,872
Base And Exercised Options Value:
$19,872
Base And All Options Value:
$19,872
Awarding Agency Name:
Department of the Interior
Performance Start Date:
2012-08-24
Description:
PALEOINDIAN EMER DATA RECOVERY FROM LS-1
Naics Code:
541620: ENVIRONMENTAL CONSULTING SERVICES
Product Or Service Code:
B509: SPECIAL STUDIES/ANALYSIS- ENDANGERED SPECIES: PLANT/ANIMAL

USAspending Awards / Financial Assistance

Business Type:
SMALL BUSINESS
Date:
2023-09-15
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
DEVELOPMENT OF A SELECTIVE PI3K-AKT-ACTIVATING NEUROTROPHIC SMALL MOLECULE DRUG, MT-002, FOR THE HEALING OF CORNEAL WOUNDS IN NEUROTROPHIC KERATITIS. - CALISTA IS DEVELOPING TOPICAL MT-002, A SELECTIVE PI3K-AKT ACTIVATOR THAT SAFELY RESTORES NORMAL WOUND HEALING IN A CLINICALLY PREDICTIVE ANIMAL MODEL OF NEUROTROPHIC KERATITIS (NK). NK CAUSES PROGRESSIVE CORNEAL DAMAGE THAT CAN LEAD TO CORNEAL PERFORATION, ULCERATION AND BLINDNESS. NK IS CAUSED BY A LOSS OF NERVE SENSATION FROM THE BRAIN TO THE EYE, DECREASING GROWTH FACTOR RELEASE THAT STIMULATES WOUND HEALING. GROWTH FACTOR DRUGS PROMOTE WOUND HEALING IN NK, AND RNGF (OXERVATE) WAS APPROVED IN 2017/18, BUT THERE ARE SEVERAL PROBLEMS THAT MT-002 SOLVES. THE PI3K-AKT PATHWAY IS ACTIVATED BY ALL GROWTH FACTORS THAT STIMULATE NORMAL WOUND HEALING. INNOVATIVELY, MT-002 BINDS SELECTIVELY TO PI3K INTRACELLULARLY, ACTIVATING THE AKT PATHWAY. MT-002 DOSES INDUCE SUSTAINED ELEVATIONS IN P-AKT FOR UP TO 2 DAYS. IN A NK MOUSE MODEL, WE TOPICALLY DOSED MT-002 EYE DROPS TO CORNEAL WOUNDS. MT-002 SAFELY RESTORED NORMAL HEALING EQUIVALENT TO RNGF. MT-002 SHOWED NO ADVERSE SAFETY EFFECTS IN A 7-DAY ASCENDING DOSE RABBIT STUDY. MT-002 IMPROVES ON RNGF BECAUSE IT IS SAFE, EFFECTIVE, INEXPENSIVE, STABLE AT ROOM TEMPERATURE AND CAN BE DOSED TWICE DAILY. THIS PROPOSAL WILL COMPLETE OUR IN VIVO TESTING OF MT-002 WITH AN ANIMAL MODEL OF NK THAT PROVIDES CLINICALLY PREDICTIVE RESULTS USING MT- 002 CLINICAL DOSE, FORMULATION AND ADMINISTRATION SCHEDULE. CORNEAL WOUND HEALING IS A PRIMARY OUTCOME IN BOTH THIS PRE-CLINICAL STUDY AND CLINICAL TRIALS, PROVIDING A MEASURE THAT ALLOWS FOR CLEAR DECISIONS ON EFFICACY. AIM 1: SYNTHESIS OF MT-002, A PEPTIDE PI3K-AKT ACTIVATOR WITH STABILITY, BIOAVAILABILITY AND EFFICACY. IN ORDER TO UNDERTAKE IN VIVO STUDIES OF AIM 2, CALISTA WILL REQUIRE ONE LARGE SCALE BATCH SYNTHESIS OF MT-002. DELIVERABLE 1: SYNTHESIS OF 100 MG OF MT-002 PEPTIDE WITH >95% PURITY AND IDENTIFICATION OF PEPTIDE MANUFACTURE ISSUES, IF ANY, FOR FOLLOW-UP TO GUIDE FOLLOW-ON PRECLINICAL AND CLINICAL STUDIES MANUFACTURING. MILESTONE 1: DECISION TO PROCEED TO AIM 2 EFFICACY STUDIES. (3 MONS; MONS 0-3) AIM 2: MT-002 CORNEAL WOUND HEALING EFFICACY IN THE RAT TRIGEMINAL NERVE MODEL. (9 MONS, MONS 3-12) WE WILL TEST MT-002 USING THE CLINICALLY PREDICTIVE ‘NISHIDA’ MODEL WHERE NK IS MODELLED BY THERMOCOAGULATION OF THE TRIGEMINAL NERVE. CLINICAL TRIALS WERE SUCCESSFUL IN THERAPIES THAT USED THIS MODEL. THIS WILL BE UNDERTAKEN IN COLLABORATION WITH CORNEAL WOUND HEALING EXPERT, DR RAJIV MOHAN AT THE UNIVERSITY OF MISSOURI. DELIVERABLE 2: MT-002 RESTORING NORMAL WOUND HEALING RATES AT 1-4 DAYS POST-DEBRIDEMENT. MILESTONE 2: DECISION TO SOLICIT A PRE-IND MEETING WITH FDA AND PROCEED WITH EXPLORATORY IND STUDIES AND ANY NEEDED FOLLOW-UP PK OR PD CHARACTERIZATION. SUCCESS IN THIS PROPOSAL WILL COMPLETE PROOF OF CONCEPT EFFICACY DATA WITH A CLINICALLY PREDICTIVE MODEL, DOSE FORM, AND FREQUENCY OF ADMINISTRATION TO JUSTIFY IND STUDIES IN A 2-YEAR PHASE 2 SBIR PROPOSAL AND/OR INVESTMENT. WE ANTICIPATE THAT CLINICAL PHASE 1 SAFETY AND PK TRIALS WILL BE COMPLETED IN 1 YEAR, PHASE 2A EFFICACY STUDIES IN ANOTHER 1 YEAR AND WE WILL PARTNER FOR PIVOTAL PHASE 2B STUDIES DURING ANOTHER 2 YEARS.
Obligated Amount:
$0
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0
Business Type:
SMALL BUSINESS
Date:
2016-11-21
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
CALCAFTOR, A CFTR STABILIZER FOR CYSTIC FIBROSIS TREATMENT
Obligated Amount:
$224,550
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0
Business Type:
SMALL BUSINESS
Date:
2014-06-04
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
CALCAFTOR, A CFTR STABILIZER FOR CYSTIC FIBROSIS TREATMENT
Obligated Amount:
$224,550
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0
Business Type:
SMALL BUSINESS
Date:
2013-08-26
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
THERAPEUTIC CORRECTION OF DELTAF508-CFTR CYSTIC FIBROSIS BY A NOVEL PDZ12 DRUG.
Obligated Amount:
$224,993
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0

Reviews Leave a review

This company hasn't received any reviews.

Date of last update: 14 Jul 2025

Sources: Rhode Island Department of State

Privacy policy Policy
About us About us Business Directory
Contacts Contact us

© 2025 riorgs.com, Part of Big Data Integrated